Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 4/20 | 0.46 |
| ▸ | MAPT | P10636 | 3/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | HTT | P42858 | 2/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | CASP1 | P29466 | 1/20 | 0.40 |
| ▸ | CASP7 | P55210 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
| ▸ | PRSS1 | P07477 | 4/20 | 0.39 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.39 |
| ▸ | MCHR1 | Q99705 | 4/20 | 0.38 |
| ▸ | HTR2C | P28335 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6204180 | 0.93 | GAA (0.47) | GAAMAPTKDM4EALDH1A1HTT | |
| SCHEMBL4198415 | 0.87 | GAA (0.55) | GAAMAPTKDM4EALDH1A1MCHR1 | |
| SCHEMBL188792 | 0.83 | GAA (0.50) | GAAMAPTKDM4EALDH1A1HTT | |
| SCHEMBL6925643 | 0.82 | GAA (0.46) | GAAMAPTKDM4EALDH1A1HTT | |
| SCHEMBL22502146 | 0.80 | GAA (0.54) | GAAMAPTKDM4EALDH1A1HTT | |
| SCHEMBL6921862 | 0.80 | GAA (0.48) | GAAMAPTKDM4EALDH1A1HTT | |
| SCHEMBL6604502 | 0.79 | ADRA1A (0.43) | GAAMAPTKDM4EHTTTSHR | |
| SCHEMBL6603753 | 0.79 | SIGMAR1 (0.52) | GAAMAPTKDM4ESIGMAR1 | |
| SCHEMBL6927309 | 0.79 | GAA (0.43) | GAAMAPTKDM4EALDH1A1HTT | |
| Hydrochloric Acid SCHEMBL22502140 | 0.79 | GAA (0.57) | GAAMAPTKDM4EALDH1A1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1343796-A4 | COMPOUNDS AND METHODS | SMITHKLINE BEECHAM CORP (US) | 2005-01-12 | — | — | EP | disclosed |
| EP-1102535-A4 | COMPOUNDS AND METHODS | SMITHKLINE BEECHAM CORP (US) | 2004-09-29 | — | — | EP | disclosed |
| US-20040038982-A1 | Compounds and methods | SMITHKLINE BEECHAM CORPORATION | 2004-02-26 | — | — | US | disclosed |
| EP-1343796-A2 | COMPOUNDS AND METHODS | SmithKline Beecham Corporation (US) | 2003-09-17 | — | — | EP | disclosed |
| EP-1001766-B1 | COMPOUNDS FOR THE TREATMENT OF CCR5-MEDIATED DISEASES | SMITHKLINE BEECHAM CORP (US) | 2003-04-09 | — | — | EP | disclosed |
| US-6515027-B1 | Ligands, agonists or antagonists, of the CC chemokine receptor CC-CKR5 | SMITHKLINE BEECHAM CORP. | 2003-02-04 | — | — | US | disclosed |
| EP-1100495-A4 | PROPENAMIDES AS CCR5 MODULATORS | SMITHKLINE BEECHAM CORP (US) | 2002-09-25 | — | — | EP | disclosed |
| US-6399656-B1 | USING A BENZOPYRAN-3-CARBOXAMIDE COMPOUND | SMITHKLINE BEECHAM CORPORATION | 2002-06-04 | — | — | US | disclosed |
| WO-2002034760-A2 | COMPOUNDS AND METHODS | SMITHKLINE BEECHAM CORPORATION (US) | 2002-05-02 | — | — | WO | disclosed |
| EP-1102535-A2 | COMPOUNDS AND METHODS | SmithKline Beecham Corporation (US) | 2001-05-30 | — | — | EP | disclosed |
| EP-1100495-A1 | PROPENAMIDES AS CCR5 MODULATORS | SMITHKLINE BEECHAM CORPORATION (US) | 2001-05-23 | — | — | EP | disclosed |
| EP-1001766-A4 | COMPOUNDS AND METHODS | SMITHKLINE BEECHAM CORP (US) | 2001-04-04 | — | — | EP | disclosed |
| EP-1001766-A1 | COMPOUNDS AND METHODS | SMITHKLINE BEECHAM CORPORATION (US) | 2000-05-24 | — | — | EP | disclosed |
| WO-2000006153-A1 | PROPENAMIDES AS CCR5 MODULATORS | SMITHKLINE BEECHAM CORPORATION (US) | 2000-02-10 | — | — | WO | disclosed |
| WO-2000006085-A2 | COMPOUNDS AND METHODS | SMITHKLINE BEECHAM CORPORATION (US) | 2000-02-10 | — | — | WO | disclosed |
| WO-1999001127-A1 | COMPOUNDS AND METHODS | SMITHKLINE BEECHAM CORPORATION (US) | 1999-01-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040038982-A1 | Compounds and methods | CCR5, CXCR3, CCR2 | GAA 3695/4885MAPT 1705/4885KDM4E 4452/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.